Medication Description: Bruneomycin (Bruneomycinum)
Antibiotic substance isolated from the culture fluid Astinomyces albus var. bruneomycini. 5-amino-6- (6-methoxy-5, 8-dihydro-7-amino-5, 8-dioxoquinol-2) -4 (2-hydroxy-3, 4-dimethoxyphenyl) -3-methyl picolinic acid.
Synonyms: Rufocromomycin, Streptonigrin.
Bruneomycin has a cytostatic effect and inhibits the development of proliferating tissue. It has pronounced antitumor activity. Inhibition of DNA synthesis plays an important role in the mechanism of drug action.
Bruneomycin (acid) is a brown crystalline powder, insoluble in water. Bruneomycin sodium salt (for injections) is a porous mass of brown color, easily soluble in water; pH of solutions 7, 0 - 7, 8.
Bruneomycin is administered intravenously for lymphogranulomatosis, reticulosarcoma and lymphosarcoma, chronic lymphocytic leukemia, Wilms tumor.
Immediately before use, the contents of the vial (0.5 mg of bruneomycin) are dissolved in 20 ml of isotonic sodium chloride solution. The drug is administered intravenously 200 to 400 μg 2 to 3 times a week. In the course of treatment 2000 - 4000 mcg.
Bruneomycin is administered to children at a dose of 5-10 µg / kg 2 times a week. Heading dose is 40 - 60 mg / kg. After 1, 5 - 2 months, repeated courses of treatment can be carried out, and the doses are reduced by 25–50% compared with the first course.
Bruneomycin can be combined with other anticancer drugs (cyclophosphamide, etc.), radiation therapy, and corticosteroids.
With the use of Bruneomycin, a decrease in appetite, nausea, and vomiting are possible (they often occur with a single dose above 500 micrograms). Reducing the dose to 200-400 µg allows you to avoid such reactions. At the end of the course may appear abdominal pain, diarrhea, stomatitis. To prevent stomatitis and other fungal infections of the mucous membranes, nystatin or levorine is prescribed.
Bruneomycin can cause severe leuko- and thrombocytopenia, and the damaging effect on hematopoiesis can occur 1 to 3 weeks after the last dose. Therefore, the introduction of the drug is stopped even with moderate leuko- and thrombocytopenia (when the number of leukocytes is less than 4 x 10 9 / l and the number of platelets is less than 120 x 10 9 / l). Blood tests are performed during and after the course of treatment with Bruneomycin.
Brunoomycin is contraindicated for leukopenia (leukocyte count below 4 x 10 9 / l) and thrombocytopenia (platelet count below 150 x 10 9 / l) associated with prior chemotherapy or radiation treatment, bone marrow damage, impaired kidney function (increased creatinine and blood urea).
Enter strictly intravenously; Necrosis is possible if it gets under the skin.
Product form: in bottles containing 0.0005 g (500 µg) of bruneomycin for injection <Bruneomycinum for injectionibus) - porous mass of brown color, easily soluble in water.
Storage: List A. In a dry, dark place at a temperature not higher than + 20 C.